VRDN - Viridian Therapeutics, Inc.
OTTAWA, Ontario, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) (“Viridian” or the “Company”) has intersected 15.05 metres at 1.09% CuEq within 40.8 metres at 0.63% CuEq, approximately 1.5 kilometres south of previous drilling at its Kraken copper-nickel-cobalt project in Labrador. The results are the first assays from the Company's southern step-out drilling program.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that it will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026. Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results and provide a business update. A w.
Shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the thirteen analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. The average 1-year price
Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency. The current valuation is demanding, with no near-term asset-based floor; future profitability hinges on successful commercialization and infrastructure sharing.
OTTAWA, Ontario, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) reports initial assay results from its 2026 drill program at the Kraken Main Zone in Labrador.
Jupiter Topco LLC acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 27,472 shares of the company's stock, valued at approximately $505,000. A number of other hedge
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Invest.
Algert Global LLC lowered its position in Viridian Therapeutics, Inc. (NASDAQ: VRDN) by 14.5% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 482,237 shares of the company's stock after selling 81,762 shares during the period. Algert Global LLC
Deutsche Bank AG bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 482,875 shares of the company's stock, valued at approximately $8,870,000. Deutsche Bank AG owned about 0.47% of Viridian Therapeutics at
OTTAWA, Ontario, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Assays are now pending from the first diamond drill holes completed as part of Viridian Metals Inc.'s (CSE: VRDN) (OTCQB: VIRMF) 2026 drill program at the Kraken project in Labrador. The initial assay submission includes the extension of hole VKS25-024, which previously returned 24.05 metres grading 0.77% CuEq¹ (0.21% Cu, 0.30% Ni, 0.04% Co) from 1 metre before terminating in mineralization (see Viridian news release dated February 26, 2025).
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve.
Zai Lab (NASDAQ: ZLAB - Get Free Report) and Viridian Therapeutics (NASDAQ: VRDN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and profitability. Analyst Ratings This is a breakdown of current
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript
The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.
Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease player with its TED franchise. Veligrotug's pivotal Phase 3 data in active and chronic TED and an FDA PDUFA date of June 30, 2026, create a near-term commercial entry point. Elegrobart, a subcutaneous follow-on asset, targets market expansion by reducing treatment barriers and is planned for a Q1 2027 BLA submission.
Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript